Clinical, Laboratory and Radiological Profile of Re-Treatment Tuberculosis

Von der Zusammensetzung zur Heilung: ein systemtechnischer Ansatz zur Entwicklung von Trägern für Tumortherapeutika

“…Zum Beispiel kann der systemische Blutdruck oder Blutfluss mit Wirkstoffen wie Angiotensin oder Nitroglycerin erhöht werden, um den interstitiellen Flüssigkeitsdruck des Tumors zu überwinden. Alternativ kann der interstitielle Flüssigkeitsdruck durch Normalisierung des Tumorgefäßsystems mit Angiogenesehemmern, z. B. dem Anti‐VEGF‐Rezeptor‐2‐Antikörper, reduziert werden.…”

Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target

“…[22][23][24][25][26][27] Vessel normalisation approaches, that promote the growth of functional vessels by enhancing oxygen and nutrient delivery to the vessels, have gained much attention in recent years as a means to improve the outcome of anti-cancer drugs. [28][29][30] As LRG1 is dispensable for developmental angiogenesis, 20 attempts to neutralise the pro-angiogenic and vasculopathic activity of LRG1 have been investigated and have led to the development of a function-blocking fully humanised IgG4 antibody against LRG1. 31 The Moss and Greenwood groups have shown that inhibiting LRG1 reverses its detrimental effects on the vasculature and leads to partial restoration of normal vascular function 21,31 and consequently improvement in the delivery of cytotoxic and immune co-therapies.…”

Improving nanoparticle diffusion through tumor collagen matrix by photo-thermal gold nanorods

“…30 However, these strategies have limitations. First, free collagenase can not be systematically administered as collagen is the structural protein in other organs 31 or it may lose activity during nanoparticle formulation process. 32 Second, conversion of large particle assemblies to small nanoparticles require intricate design chemistry to minimize degradation during circulation 33 and rapid release 34 within tumor matrix before being cleared by elevated IFP.…”